Rezolute Inc

Rezolute Inc a clinical stage biopharmaceutical company develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States The companys lead product candidate is RZ358 a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism an ultrarare pediatric genetic disorder It is also developing RZ402 a selective and potent plasma kallikrein inhibitor which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema The company was formerly known as AntriaBio Inc and changed its name to Rezolute Inc in December 2017 Rezolute Inc was founded in 2010 and is headquartered in Redwood City California